Ecotoxicological efficiency of advanced ozonation processes with TiO2 and black light used in the degradation of carbamazepine

The aim of the present study was to evaluate the ecotoxicological efficiency of two advanced ozonation processes (AOzPs), the catalytic ozonation (O3/TiO2) and the photocatalytic ozonation (O3/TiO2/black light), in the remotion of carbamazepine. The ecotoxicological efficiency was assessed through the use of lethal and sublethal assays with species Vibrio fischeri and Daphnia magna. Results demonstrated that the AOzPs presented an efficiency of carbamazepine removal higher than 99% (carbamazepine < 2 μg/L) after 12 min of treatment. Relatively to ecotoxicological evaluation, application of acute assay to V. fischeri and chronic assay to D. magna allowed us to highlight that these technologies may form some transformation products that induce toxicity in the bacteria and the crustacean, once these organisms exposed to the undiluted solutions (100%) showed a decrease in the bioluminescence (vibrio) and end up dying before and during the first reproduction (daphnia). Despite that, when the chronic results obtained with the diluted solutions (50 and 25%; important to assess a more realistic scenario considering the dilution factor at the environment) were analyzed, no mortality at the mothers was observed. Compared to a carbamazepine solution (200 μg/L), diluted solutions improved of the reproduction parameters, and no toxic effects in the juvenoid system and in the embryonic development were observed. Relatively to the ecdysteroid effect of a carbamazepine solution (200 μg/L), only the photocatalytic ozonation treatment was able to remove the action of the drug. These results highlight the importance of complementing chemical analysis with ecotoxicological bioassays to assess the best technology to improve the surface water and effluent quality

Thermocatalytic CO2 Conversion over a Nickel-Loaded Ceria Nanostructured Catalyst: A NAP-XPS Study

Despite the increasing economic incentives and environmental advantages associated to their substitution, carbon-rich fossil fuels are expected to remain as the dominant worldwide source of energy through at least the next two decades and perhaps later. Therefore, both the control and reduction of CO2 emissions have become environmental issues of major concern and big challenges for the international scientific community. Among the proposed strategies to achieve these goals, conversion of CO2 by its reduction into high added value products, such as methane or syngas, has been widely agreed to be the most attractive from the environmental and economic points of view. In the present work, thermocatalytic reduction of CO2 with H-2 was studied over a nanostructured ceria-supported nickel catalyst. Ceria nanocubes were employed as support, while the nickel phase was supported by means a surfactant-free controlled chemical precipitation method. The resulting nanocatalyst was characterized in terms of its physicochemical properties, with special attention paid to both surface basicity and reducibility. The nanocatalyst was studied during CO2 reduction by means of Near Ambient Pressure X-ray Photoelectron Spectroscopy (NAP-XPS). Two different catalytic behaviors were observed depending on the reaction temperature. At low temperature, with both Ce and Ni in an oxidized state, CH4 formation was observed, whereas at high temperature above 500 degrees C, the reverse water gas shift reaction became dominant, with CO and H2O being the main products. NAP-XPS was revealed as a powerful tool to study the behavior of this nanostructured catalyst under reaction conditions

Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study

Purpose: The DIANA study aimed to evaluate how often antimicrobial de-escalation (ADE) of empirical treatment is performed in the intensive care unit (ICU) and to estimate the effect of ADE on clinical cure on day 7 following treatment initiation. Methods: Adult ICU patients receiving empirical antimicrobial therapy for bacterial infection were studied in a prospective observational study from October 2016 until May 2018. ADE was defined as (1) discontinuation of an antimicrobial in case of empirical combination therapy or (2) replacement of an antimicrobial with the intention to narrow the antimicrobial spectrum, within the first 3 days of therapy. Inverse probability (IP) weighting was used to account for time-varying confounding when estimating the effect of ADE on clinical cure. Results: Overall, 1495 patients from 152 ICUs in 28 countries were studied. Combination therapy was prescribed in 50%, and carbapenems were prescribed in 26% of patients. Empirical therapy underwent ADE, no change and change other than ADE within the first 3 days in 16%, 63% and 22%, respectively. Unadjusted mortality at day 28 was 15.8% in the ADE cohort and 19.4% in patients with no change [p = 0.27; RR 0.83 (95% CI 0.60-1.14)]. The IP-weighted relative risk estimate for clinical cure comparing ADE with no-ADE patients (no change or change other than ADE) was 1.37 (95% CI 1.14-1.64). Conclusion: ADE was infrequently applied in critically ill-infected patients. The observational effect estimate on clinical cure suggested no deleterious impact of ADE compared to no-ADE. However, residual confounding is likely